Retatrutide Unimolecular GIP/GLP-1/Glucagon Tri-Agonist Shows Significant Weight Loss and Glycemic Efficacy in Phase 3 Trials

Retatrutide represents a novel approach in metabolic disease management, building upon the success of existing GLP-1 receptor agonists (GLP-1RAs) for type 2 diabetes (T2D) and obesity. While current therapies offer significant benefits, there remains a need for agents with enhanced efficacy, particularly in achieving substantial weight loss and comprehensive metabolic control. This unimolecular poly-agonism strategy, targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors, aims to leverage the synergistic effects of these pathways to improve both glycaemic efficacy and body composition. This review explores how combining these receptor engagements could offer superior outcomes by addressing multiple facets of metabolic dysregulation.

This critical narrative review synthesized molecular engineering, pharmacokinetics, pharmaceutical development, and clinical evidence for Retatrutide (LY3437943), an investigational once-weekly, lipidated 39-residue peptide. The review examined data available up to September 11, 2026, focusing on five reported Phase 3 trials. It incorporated the full peer-reviewed report for TRANSCEND-T2D-1, which assessed glycaemic efficacy in early type 2 diabetes. For obesity outcomes, the review relied on sponsor topline disclosures from trials like TRIUMPH-1 and TRIUMPH-4, which reported primary outcomes related to weight reduction.

Written by TitrateLab, separately from the study summarized above.